Quantcast
Last updated on April 17, 2014 at 16:26 EDT

Latest Opioid Stories

2013-10-02 11:03:56

Study first to assess long-term use of prescription painkillers for chronic, non-cancer pain management among patients pre- and post-obesity surgery Chronic use of prescription painkillers, also known as opioids, among obese patients prior to bariatric surgery continues after surgery, according to a new Kaiser Permanente study published today in the Journal of the American Medical Association. Researchers examined the electronic medical records of 11,719 obese patients who underwent...

2013-10-02 10:27:47

In a group of patients who took chronic opioids for noncancer pain and who underwent bariatric surgery, there was greater chronic use of opioids after surgery compared with before, findings that suggest the need for proactive management of chronic pain in these patients after surgery, according to a study in the October 2 issue of JAMA. "Bariatric surgery is used to treat obesity, as well as its comorbid conditions such as cardiovascular and metabolic diseases and chronic pain. Bariatric...

2013-09-30 23:43:38

On October 1, 2013 a national coalition of advocate organizations called the Fed Up! Coalition will hold a major rally to call for an immediate, coordinated and comprehensive federal response to the epidemic of opioid addiction and overdose deaths. The Rally will run from noon until 2:00 p.m. in Upper Senate Park at the Capitol in Washington D.C. Washington, D.C. (PRWEB) September 30, 2013 As the death toll from the opioid epidemic climbs, grief turns to action at FED UP! Rally in D.C....

2013-09-30 08:28:25

SAN FRANCISCO, Sept. 30, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that AstraZeneca announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for Naloxegol, an investigational peripherally-acting mu-opioid receptor antagonist, which has been specifically designed for the treatment of opioid-induced constipation (OIC) for adult patients 18 years and older, including patients with inadequate response to...

2013-09-26 16:26:53

Company to Host Conference Call on Thursday, September 26th at 1:30 PM Pacific Time/4:30 PM Eastern Time to Discuss Results SAN FRANCISCO, Sept. 26, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced the preliminary topline results from a Phase 2 study of NKTR-181 for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis of the knee. The Phase 2 study utilized a double-blind, placebo-controlled, randomized withdrawal study design to assess...

2013-09-25 08:30:22

Travis C. Mickle, Ph.D., President & CEO of KemPharm, to Present Results at The 7th Annual Pain Therapeutics Summit East NORTH LIBERTY, Iowa and BOSTON, Sept. 25, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, today announced results from a second pivotal clinical study of KP201 (benzhydrocodone hydrochloride and acetaminophen) in preparation for a New Drug Application...

2013-09-24 08:32:11

STAMFORD, Conn., Sept. 24, 2013 /PRNewswire/ -- Purdue Pharma L.P. announced that the U.S. Food and Drug Administration (FDA) approved a new 15 mcg/hour dosage strength of Butrans® (buprenorphine) Transdermal System CIII, which will provide an additional titration option for healthcare professionals. Four strengths of Butrans will now be available: 5, 10, 15 and 20 mcg/hour. Purdue expects to launch Butrans 15 mcg/hour commercially in the U.S. in October 2013. Butrans is indicated for the...

2013-09-24 08:31:37

Lightlake Therapeutics moves forward in collaboration with NIDA for novel intranasal naloxone application to reverse overdoses LONDON, Sept. 24, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that the Company has begun a two-week clinical trial designed to evaluate the pharmacokinetic properties of Lightlake's...

2013-09-17 16:24:16

CHICAGO, Sept. 17, 2013 /PRNewswire-USNewswire/ -- The physicians of the American Academy of Pain Medicine (AAPM) hailed long-awaited labeling changes and other steps taken by the U.S. Food and Drug Administration (FDA) last week to enhance safety in the prescribing of extended-release and long-acting (ER/LA) opioids. AAPM further supported the Agency's decision to deny portions of a citizen petition seeking dosage and treatment duration limits that would have applied to every patient...

Opioid Prescriptions Nearly Double
2013-09-16 11:11:23

Michael Harper for redOrbit.com - Your Universe Online More research has been released this week which examines the extent of America’s growing addiction to opioid painkillers. In the last three weeks two studies have been published highlighting this disturbing trend and warning of the dangers therein. A study published last week found that the number of opioid prescriptions for non-cancer pain has almost doubled in the past decade. What’s more, prescriptions for non-opioid...